This site is intended for healthcare professionals only

DiabetesontheNet Logo
×
News
Share this article
Share on facebook
Share on twitter
Share on email
Share on print

UK Kidney Association releases guideline on SGLT2 inhibitor use

The UK Kidney Association has released its Clinical Practice Guideline on sodium–glucose cotransporter 2 (SGLT2) inhibitor use in adults with kidney disease. Studies have demonstrated that these agents have particular efficacy at reducing  risk of kidney disease progression in people with type 2 diabetes and albuminuric diabetic kidney disease, and that these benefits may extend to certain types of albuminuric renal disease irrespective of the presence of diabetes.

Therefore, the aim of the guidelines is to facilitate rapid and safe use of SGLT2 inhibitors in the context of chronic kidney disease, focusing on the  potential to modify risk of kidney disease progression, and to support the safe implementation of SGLT2 inhibitors in clinical practice.

Click here to read the guideline.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.